Rapport Therapeutics (RAPP) Net Cash Flow (2023 - 2026)

Rapport Therapeutics (RAPP) has reported Net Cash Flow for 4 consecutive years, with $25.4 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Net Cash Flow rose 3080.35% year-over-year to $25.4 million; the TTM figure through Mar 2026 stood at $20.5 million (up 222.74% YoY), while the FY2025 annual figure was -$4.2 million, up 68.82% from the prior year.
• Net Cash Flow improved to $25.4 million in Q1 2026 per RAPP's latest filing, from -$198.7 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $196.3 million in Q3 2025 and bottomed at -$198.7 million in Q4 2025.
• Historically, Net Cash Flow has averaged -$124272.7 across 4 years, with a median of $4.1 million in 2024.
• Annual changes were most pronounced in 2025 — Net Cash Flow plunged 1236.09% — and 2026, when it soared 3080.35%.
• Rapport Therapeutics' Net Cash Flow stood at -$89.2 million in 2023, then soared by 119.62% to $17.5 million in 2024, then slumped by 1236.09% to -$198.7 million in 2025, then surged by 112.79% to $25.4 million in 2026.
• Business Quant data shows RAPP's Net Cash Flow at $25.4 million in Q1 2026, -$198.7 million in Q4 2025, and $196.3 million in Q3 2025.